Lilly reports positive interim results from Heart-2 trial of VERVE-102

Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102. The study involved 35 participants with heterozygous familial hypercholesterolaemia or premature coronary artery disease. The therapy was generally well tolerated, with no treatment-related serious adverse events reported. Credit: SmartPhotoLab / Shutterstock.com. Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102, an investigational therapy intended as a one-time treatment for hypercholesterolaemia. The single-ascending-dose, open-label trial showed notable reductions in LDL-cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) protein after a single…

Source: Clinical Trials Arena